Menu

Verhaagen Group

Innovation fund for the development of gene therapy

The Innovation Fund Noord-Holland has awarded a subsidy to a collaborative project between the Amsterdam biotech start-up SanaGen B.V. and the research groups of Joost Verhaagen from the NIN and Jan Voorberg from Sanquin.

This grant supports the development of gene therapy for rare bleeding disorders. This collaborative project is co-financed by the PPP allowance from the Top Sector Life Sciences & Health.

The Top Sector Life Sciences & Health stimulates innovative research by guiding and supporting public-private partnerships in the Life Sciences & Health sector.

More information about the funding can be found on the website of SanaGen.

Share

Verhaagen Group

This laboratory performs basic and translational research with the aim to advance the field of restorative neuroscience and neurology. We focus on the cellular and molecular mechanisms that underlie degeneration, regeneration and plasticity of the central and peripheral nervous system. A significant portion of research is dedicated to the identification of novel genes and molecular pathways that affect the capacity of the nervous system to regenerate. Genomics, bioinformatics and high-throughput functional screening are key components of our research strategy and gene therapy based on advanced viral vector technology is applied to validate the therapeutic efficacy of molecular targets in clinically relevant animal models of neurodegeneration and repair. The ultimate goal of the Laboratory for Neuroregeneration is to develop novel therapeutic strategies to promote regeneration and plasticity of injured axons.

Read more